Manipulation of the Complement System for Benefit in Sepsis

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">  Treatment</td><td align="center">Amount injected i.v.</td><td align="center">Survival (day 5)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Normal IgG<sub>2</sub></td><td align="center">1,000 <i>μ</i>g</td><td align="center">10%</td></tr><tr><td align="left">Anti-rat C5a mAb</td><td align="center">1,000 <i>μ</i>g</td><td align="center">70%</td></tr><tr><td align="left">Anti-rat C5a mAb</td><td align="center">400 <i>μ</i>g</td><td align="center">65%</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>
              *Monoclonal IgG<sub>2</sub> obtained by immunization of C57Bl/6 mice with recombinant rat C5a. The antibody was of high affinity based on plasma resonance measurements using a biosensor instrument.<br/></td></tr></table>

Critical Care Research and Practice

tab3

Table 3

Table 3: Manipulation of the Complement System for Benefit in Sepsis 